REGN 10-K Annual Reports

Regeneron Pharmaceuticals, Inc. reported solid financial performance for the fiscal year ending December 31, 2025, with revenues reaching $14.34 billion and net income at $4.50 billion. The company's strategic focus on scientific innovation and integrated development, manufacturing, and commercialization capabilities continues to drive growth. Key products like Dupixent and EYLEA HD demonstrated strong performance, contributing significantly to the company's top-line results, despite increased competition and the ongoing transition from EYLEA to EYLEA HD. The company also highlighted its robust pipeline with numerous product candidates in various stages of clinical development across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron continues to invest heavily in research and development to fuel future growth. However, investors should be aware of potential headwinds. The company is heavily reliant on its flagship products, EYLEA and Dupixent, and faces significant competition, including from biosimilars for EYLEA. Regulatory and manufacturing challenges were noted, particularly concerning a third-party manufacturer (Catalent) that led to delays in FDA approvals for EYLEA HD's pre-filled syringe and Ordspono. The company is actively managing these issues by onboarding new manufacturers and addressing regulatory feedback. The evolving healthcare landscape, including pricing pressures and potential regulatory changes, also presents risks that investors should monitor.

Regeneron Pharmaceuticals, Inc. reported robust financial performance for the fiscal year ended December 30, 2024, with revenues reaching $14.2 billion and net income of $4.4 billion, marking a significant increase from the prior year. The company's flagship products, EYLEA/EYLEA HD and Dupixent, continue to be key revenue drivers, with Dupixent in particular showing strong growth in collaboration revenue. Regeneron's extensive pipeline remains a focus, with numerous product candidates in various stages of clinical development across multiple therapeutic areas. The company is also actively managing its manufacturing and supply chain capabilities, investing in facility expansions and process validation to support future growth. Shareholder returns were bolstered by a new share repurchase program and the initiation of a quarterly dividend, indicating confidence in the company's financial health and future prospects.

Regeneron Pharmaceuticals, Inc. (REGN) reported total revenues of $13,117.2 million for the year ended December 31, 2023, an increase of approximately 7.8% compared to the prior year. This growth was primarily driven by strong performance in Dupixent and the launch of EYLEA HD. Net income for the year was $3,953.6 million, resulting in diluted earnings per share of $34.77. The company continues to invest heavily in research and development, with expenses increasing to $4,439.0 million, reflecting progress across its diverse pipeline of product candidates in various therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron maintains a robust financial position, with significant cash and marketable securities, and is actively managing its capital structure through share repurchases.

Regeneron Pharmaceuticals, Inc. (REGN) reported revenues of $12.17 billion for the year ended December 31, 2022, a decrease of approximately 24% compared to $16.07 billion in 2021. This decline was primarily driven by a significant drop in REGEN-COV sales, which were $7.57 billion in 2021 and largely absent in 2022, coupled with a modest increase in EYLEA and Dupixent sales. Net income also decreased substantially from $8.08 billion in 2021 to $4.34 billion in 2022, reflecting the reduced revenues and increased investment in research and development. The company continues to invest heavily in its robust pipeline, with research and development expenses increasing by approximately 25% year-over-year. Key products like EYLEA and Dupixent showed growth, indicating strong performance in core therapeutic areas. Regeneron is also actively managing its capital, evidenced by significant share repurchases and capital expenditures aimed at expanding its manufacturing capacity. The company remains focused on innovation and the development of new therapies across a broad range of serious diseases.

Regeneron Pharmaceuticals, Inc. reported strong financial performance for the fiscal year ended December 31, 2021, with revenues more than doubling year-over-year to $16.1 billion and net income reaching $8.1 billion. This significant growth was largely driven by substantial sales of REGEN-COV, its antibody cocktail for COVID-19, which generated $7.6 billion in revenue. Key commercial products like EYLEA and Dupixent also demonstrated robust growth, with EYLEA sales reaching $9.4 billion and Dupixent sales hitting $6.2 billion globally (recorded by Sanofi). The company's diverse pipeline continues to advance, with multiple product candidates in late-stage clinical development across various therapeutic areas, including ophthalmology, immunology, inflammation, and oncology. Looking ahead, Regeneron is focused on expanding its marketed products' reach and advancing its pipeline. While REGEN-COV's utility has been impacted by the Omicron variant, the company is actively developing next-generation antibodies. The company maintains a strong financial position with significant cash reserves and has continued its share repurchase program. Investors should monitor the ongoing performance of EYLEA and Dupixent, the success of pipeline advancement, and potential impacts from regulatory changes and competition.

Regeneron Pharmaceuticals, Inc. (REGN) reported robust financial performance in its 2020 10-K filing, with revenues reaching $8.5 billion and net income soaring to $3.5 billion, representing significant year-over-year growth. This strong financial result was primarily driven by the exceptional performance of its key products, EYLEA and Dupixent, which continue to show substantial net product sales. The company also made significant progress in its pipeline, with a notable mention of REGEN-COV receiving Emergency Use Authorization (EUA) for COVID-19 treatment, contributing to its revenue stream. Regeneron's commitment to scientific innovation is evident in its extensive clinical development programs across various therapeutic areas, including ophthalmology, immunology, inflammation, and oncology. Looking ahead, Regeneron is well-positioned due to its strong financial footing and a diversified product portfolio and pipeline. The company continues to invest heavily in research and development, aiming to bring new treatments to patients. Investors should note the ongoing collaborations with major pharmaceutical companies like Sanofi and Bayer, which are crucial for global commercialization and revenue sharing. Despite the positive outlook, the company faces inherent risks associated with drug development, regulatory approvals, market competition, and the ongoing impact of the COVID-19 pandemic, all of which are detailed in the risk factors section.

Regeneron Pharmaceuticals, Inc. (REGN) reported solid revenue growth in 2019, driven by strong performance in its key products, particularly EYLEA and Dupixent. Total revenues reached $7.86 billion, a significant increase from $6.71 billion in 2018, demonstrating continued market acceptance and expansion of its therapeutic offerings. Net income, however, saw a decrease to $2.12 billion from $2.44 billion in the prior year, primarily due to increased research and development (R&D) investments, including a substantial upfront payment for a new collaboration. The company continues to invest heavily in its robust pipeline, with 22 product candidates in clinical development across various therapeutic areas. Significant R&D expenditure, rising from $2.19 billion in 2018 to $3.04 billion in 2019, underscores Regeneron's commitment to innovation and future growth. Key collaborations with Sanofi and Bayer remain crucial for its commercial strategies, contributing significantly to revenue and providing global reach for its products. The company ended the year with a strong cash position, providing financial flexibility for ongoing development and strategic initiatives.

Regeneron Pharmaceuticals, Inc. (REGN) demonstrated robust financial performance in 2018, with revenues reaching $6.71 billion and net income soaring to $2.44 billion, a significant increase from the previous year. This growth was primarily driven by strong sales of its key products, notably EYLEA, which continues to be the company's primary revenue generator, and increasing contributions from Dupixent and Libtayo. The company's commitment to innovation is evident in its extensive pipeline, with 21 product candidates in clinical development across various therapeutic areas. Collaborations with major pharmaceutical companies like Sanofi and Bayer remain crucial to Regeneron's commercialization strategy, particularly for products like EYLEA outside the U.S. and Dupixent, Praluent, and Kevzara globally. Looking ahead, Regeneron is focused on advancing its pipeline and expanding the indications for its existing products. Key developments in 2018 included positive trial results for Dupixent in adolescent atopic dermatitis and asthma, and for Praluent in cardiovascular risk reduction, with regulatory submissions for these expanded uses underway. The company also received FDA approval for Libtayo for advanced cutaneous squamous cell carcinoma. Investors should monitor the progress of ongoing clinical trials, regulatory decisions, and the impact of competition, especially potential biosimilars for EYLEA, as these factors will significantly influence future financial performance.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance for the fiscal year 2017, driven by significant growth in its key products, EYLEA and Dupixent. Total revenues reached $5.87 billion, a substantial increase from $4.86 billion in 2016, with net income rising to $1.20 billion, or $10.34 per diluted share, up from $895.5 million, or $7.70 per diluted share, in the prior year. The company highlighted substantial progress across its diverse pipeline, with key advancements in its antibody-based programs. Dupixent received regulatory approvals in the U.S. and EU for atopic dermatitis and positive Phase 3 results for asthma, with submissions for the latter also made to the FDA. EYLEA saw continued sales growth and filed for a 12-week dosing interval. Additionally, cemiplimab showed promising results in advanced cutaneous squamous cell carcinoma and is progressing towards BLA submission. The company also advanced several other product candidates in clinical development for various serious diseases, underscoring its commitment to innovation and expanding its therapeutic offerings. Regeneron's robust performance is underpinned by its proprietary VelociSuite® technology platforms and strategic collaborations. The company's focus on scientific discovery and development, coupled with expanding manufacturing capabilities and a strong balance sheet, positions it well for future growth. Despite facing competitive pressures and regulatory complexities inherent in the biopharmaceutical industry, Regeneron's strategic advancements and financial health present a positive outlook for investors.

Regeneron Pharmaceuticals, Inc. (REGN) reported a strong financial performance in 2016, with revenues increasing significantly to $4.86 billion, up from $4.10 billion in 2015, and net income growing to $895.5 million, or $7.70 per diluted share, compared to $636.1 million, or $5.52 per diluted share, in 2015. This growth was primarily driven by EYLEA, which saw a 24.2% increase in U.S. net sales and remains the market-leading anti-VEGF therapy. The company also made significant advancements across its pipeline, including positive Phase 3 data for Dupixent in atopic dermatitis, with regulatory decisions pending. Key strategic initiatives included expanding research and development capabilities and forging new collaborations to bolster its drug discovery and development pipeline. The company's robust pipeline and strong commercial performance of EYLEA position it for continued growth. Key developments in 2016 include progress in multiple late-stage clinical programs, such as Praluent (positive Phase 3 data and expanded international approvals), Dupixent (positive Phase 3 data and FDA priority review), and sarilumab (though facing a Complete Response Letter for manufacturing deficiencies, the underlying data was positive). Regeneron also advanced early-stage research with collaborations in gene editing and immune-cell therapeutics, alongside substantial investment in genomics, highlighting a commitment to scientific innovation and expanding its therapeutic reach.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance in 2015, driven primarily by significant growth in its lead product, EYLEA. EYLEA demonstrated robust sales growth of 54% year-over-year, solidifying its position as the market-leading anti-VEGF therapy in the U.S. The company also achieved key regulatory milestones, including U.S. and European approval for Praluent (alirocumab) for LDL cholesterol reduction, marking a significant entry into the cardiovascular market. The company's pipeline advanced with positive Phase 3 data for sarilumab in rheumatoid arthritis and progressed dupilumab in atopic dermatitis and asthma, indicating strong future growth potential. Regeneron's commitment to innovation is further evidenced by its advanced genomics initiatives and strategic collaborations. Financially, the company saw substantial increases in both total revenues and net income, reflecting its successful commercialization efforts and ongoing pipeline development. Investors should note the continued reliance on EYLEA for a substantial portion of revenue, alongside the significant potential of Praluent and its robust pipeline. The company's strong financial results and strategic partnerships position it well for future growth, though ongoing regulatory and competitive landscapes remain key factors to monitor.

Regeneron Pharmaceuticals, Inc. demonstrated robust revenue growth in 2014, reaching $2,819.6 million, an increase from $2,104.7 million in 2013, primarily driven by strong performance in its EYLEA franchise. EYLEA's net product sales in the U.S. reached $1,736.4 million in 2014, with significant international sales of $1,038.5 million contributing to overall growth. The company also reported progress in its late-stage pipeline, with key clinical trial updates for PRALUENT (alirocumab) for cholesterol reduction and sarilumab for rheumatoid arthritis, alongside ongoing development for dupilumab in allergic conditions. While net income decreased to $348.1 million ($3.07 per diluted share) in 2014 from $424.4 million ($3.81 per diluted share) in 2013, this was largely attributed to the absence of a significant tax benefit recorded in 2012. Regeneron's strategic focus remains on leveraging its VelociSuite technologies for drug discovery and expanding its therapeutic reach into areas with high unmet medical needs. The company also highlighted its human genetics initiative as a key long-term growth driver.

Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth in 2013, primarily driven by its flagship product, EYLEA. Net revenues reached $2.1 billion, a significant increase from $1.38 billion in 2012, showcasing EYLEA's rapid market penetration in ophthalmology for wet AMD and macular edema. The company's product pipeline is robust, with 16 product candidates in clinical development, many of which are being developed in collaboration with major pharmaceutical partners like Sanofi and Bayer HealthCare. Key pipeline candidates include those for rheumatoid arthritis (sarilumab), LDL cholesterol reduction (alirocumab), and various allergic and immune conditions (dupilumab), indicating a diversified future revenue potential beyond EYLEA. While Regeneron achieved profitability in 2012 and maintained it in 2013, significant investment in research and development continues to be a primary focus, underscoring the company's commitment to innovation and long-term growth.

Regeneron Pharmaceuticals, Inc. (REGN) reported a significant financial turnaround in 2012, achieving profitability with a net income of $750.3 million, a stark contrast to the net loss of $221.8 million in 2011. This profitability was largely driven by the strong performance of its lead product, EYLEA, which generated $837.9 million in U.S. net sales in 2012, following its launch in late 2011. The company also benefited from a substantial income tax benefit of $335.8 million due to the release of its deferred tax asset valuation allowance, and milestone payments from its collaboration partners, Sanofi and Bayer HealthCare. The company's pipeline remains robust, with 13 product candidates in clinical development, primarily monoclonal antibodies. Key collaborations with Sanofi and Bayer HealthCare are crucial for its ongoing research and commercialization efforts, particularly for EYLEA outside the U.S. and for ZALTRAP. Despite the positive financial results, Regeneron faces ongoing risks related to competition, regulatory approvals for new indications and products, and the potential for adverse outcomes in ongoing patent litigations, notably with Genentech.

Regeneron Pharmaceuticals, Inc. (REGN) reported its 2011 annual results, showcasing significant progress and strategic advancements. The company achieved a major milestone with the U.S. FDA approval and launch of EYLEA® for wet age-related macular degeneration (wet AMD), a condition with a substantial market. This launch began generating product sales in the fourth quarter of 2011. Alongside EYLEA®, ARCALYST® continued its commercialization for rare auto-inflammatory conditions, though its future sales are not expected to be significant. The company also advanced its pipeline, with ZALTRAP® submitted for marketing approval in the U.S. and EU for metastatic colorectal cancer. Financially, Regeneron continued to invest heavily in research and development, leading to an increase in its net loss for 2011 compared to 2010, primarily driven by higher R&D and selling, general, and administrative expenses. However, the company bolstered its financial position by raising significant capital through a private placement of convertible senior notes, indicating a focus on funding its ongoing development programs and potential commercialization efforts. The strong collaboration with Sanofi and Bayer HealthCare remained a key revenue driver, providing substantial funding for research and development activities. Overall, the report highlights Regeneron's transition towards a commercial-stage biopharmaceutical company, marked by the successful launch of a key product and a robust pipeline. While R&D investments are impacting near-term profitability, the company's strategic partnerships and capital raise position it for future growth, contingent on the successful development and commercialization of its product candidates.

Regeneron Pharmaceuticals, Inc. (REGN) presented its 2010 annual report, highlighting significant progress in its clinical pipeline and strategic collaborations. The company continues to advance its key product candidates, particularly VEGF Trap-Eye for ophthalmologic diseases and ARCALYST® for inflammatory conditions like gout flares. The collaboration with Bayer HealthCare for VEGF Trap-Eye yielded positive Phase 3 results in wet age-related macular degeneration (wet AMD), with regulatory submissions planned for 2011. Similarly, positive Phase 3 data for ARCALYST® in gout prevention provides a pathway for future regulatory filings. The extensive collaboration with sanofi-aventis continues to drive the development of multiple antibody candidates across various therapeutic areas, supported by substantial funding from sanofi-aventis, underscoring a strong partnership for pipeline advancement. Financially, Regeneron reported a net loss for 2010, primarily due to significant investments in research and development. However, collaboration revenue and technology licensing revenue provided substantial financial support, complemented by a strong cash position. The company anticipates continued substantial expenses for R&D and preparations for potential commercialization, emphasizing the critical role of its ongoing collaborations for funding. Investors should note the inherent risks in drug development, including clinical trial outcomes, regulatory approvals, and competitive pressures, as outlined in the 'Risk Factors' section.

Regeneron Pharmaceuticals, Inc. (REGN) filed an amendment to its 2009 Annual Report (10-K/A) on June 1, 2010. This filing primarily provides access to the company's exhibits and financial statement schedules. For investors, the most critical information would be found in the detailed financial statements themselves, which are typically included or referenced in the 10-K, and the exhibits which may contain material agreements, contracts, and other documents that provide deeper insight into the company's operations, strategic partnerships, and potential liabilities or opportunities. While this specific amendment focuses on the supplementary sections, a thorough investor analysis would require reviewing the complete 10-K filing for the period ending December 30, 2009. This would include management's discussion and analysis of financial condition and results of operations, risk factors, and details on the company's product pipeline and development stage. Investors should look for information regarding revenue generation, research and development expenditures, clinical trial progress, and any significant collaborations or licensing agreements that could impact future growth.

Regeneron Pharmaceuticals, Inc. (REGN) in its 2010 10-K filing highlights a diversified pipeline with one marketed product, ARCALYST®, for rare autoinflammatory conditions (CAPS). The company is heavily invested in late-stage clinical development with three key candidates: rilonacept for gout flares, VEGF Trap-Eye for eye diseases (in collaboration with Bayer HealthCare), and aflibercept (VEGF Trap) for oncology (in collaboration with sanofi-aventis). Regeneron leverages its proprietary VelociSuite™ technology for antibody discovery, with an expanded collaboration with sanofi-aventis aiming to advance numerous new antibody candidates into clinical development over the next eight years. The company's financial health relies significantly on collaboration revenues, with substantial research and development expenses driving ongoing losses, a pattern expected to continue in the near term. Despite these losses, Regeneron maintains a healthy cash position, supported by significant upfront and milestone payments from its major partners. Investors should note the company's ongoing reliance on strategic collaborations for both funding and development, as well as the inherent risks associated with drug development, regulatory approvals, and market competition.

Regeneron Pharmaceuticals, Inc. (REGN) reported its 2008 fiscal year results, highlighting significant progress in its drug development pipeline and strategic collaborations. The company received FDA approval for its first commercial drug, ARCALYST® (rilonacept) Injection for Subcutaneous Use, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). This marks a crucial milestone, transitioning Regeneron towards becoming a commercial-stage biopharmaceutical company. Financially, Regeneron continued to invest heavily in research and development, which contributed to an operating loss for the year. However, revenue streams from key collaborations, particularly with sanofi-aventis and Bayer HealthCare, provided substantial funding for these R&D efforts. The company's cash position decreased year-over-year, primarily due to significant R&D spending and capital expenditures, alongside the repayment of convertible notes. Investors should monitor the progression of ARCALYST sales and the continued success of its strategic partnerships for future growth.

Regeneron Pharmaceuticals, Inc. reported a net loss of $105.6 million for the year ended December 31, 2007, a slight increase from the $102.3 million loss in 2006. The company's revenue significantly increased to $125 million in 2007, driven by substantial upfront payments and progress payments from collaborations with sanofi-aventis and Bayer HealthCare, alongside technology licensing revenue. Research and development expenses also rose to $201.6 million, reflecting increased investment in clinical programs, particularly for ARCALYST™, aflibercept, and VEGF Trap-Eye, as well as the advancement of its antibody programs. Financially, Regeneron ended 2007 with a stronger cash position, holding $846.3 million in cash, cash equivalents, and marketable securities, bolstered by significant funding from its collaborations. The company faces a substantial debt maturity in October 2008 with $200 million in convertible notes. Despite ongoing losses, the company anticipates meeting its operating needs through at least 2012, supported by its substantial cash reserves and expected collaboration funding.

Regeneron Pharmaceuticals, Inc. reported a net loss of $102.3 million for the fiscal year ended December 31, 2006, an increase from the previous year's loss of $95.4 million. Total revenues decreased slightly to $63.4 million from $66.2 million in 2005, primarily due to the expiration of contract manufacturing agreements. The company continues to invest heavily in research and development, with a focus on three key programs: IL-1 Trap for inflammatory diseases, VEGF Trap for oncology (in collaboration with sanofi-aventis), and VEGF Trap-Eye for eye diseases (in collaboration with Bayer HealthCare). The company's financial position remains stable, with approximately $522.9 million in cash, cash equivalents, and marketable securities at the end of 2006, bolstered by a successful public offering in November 2006. However, Regeneron faces significant risks, including the high cost and uncertainty of drug development, potential competition, and the need for future financing. The company has no products currently approved for sale, and its strategy hinges on advancing its pipeline candidates through clinical trials and regulatory approvals. Key developments during 2006 include positive Phase 3 data for IL-1 Trap in Cryopyrin-Associated Periodic Syndromes (CAPS), with a BLA submission anticipated in Q2 2007. Significant progress was also made in the VEGF Trap programs, with Phase 2 studies ongoing and plans for Phase 3 trials initiated. The company also entered into a collaboration with Bayer HealthCare for the VEGF Trap-Eye, receiving a $75 million upfront payment. Regeneron's proprietary VelocImmune technology is also being leveraged for future antibody candidates.

Regeneron Pharmaceuticals, Inc. (REGN) in its 2005 10-K filing highlights a significant shift in its financial performance and strategic focus. The company reported a substantial net loss of $95.4 million for the year ended December 31, 2005, a notable downturn from the net income of $41.7 million in the prior year. This change is largely attributable to decreased revenues from key collaborations, particularly the termination of substantial revenue streams from Novartis and the reduced activities with Procter & Gamble, coupled with increased research and development expenses. The company also adopted new accounting standards for stock-based compensation, impacting reported expenses. Operationally, Regeneron is advancing its core therapeutic candidates: VEGF Trap for oncology (in collaboration with sanofi-aventis), VEGF Trap-Eye for eye diseases, and IL-1 Trap for inflammatory conditions. The VEGF Trap-Eye program showed positive preliminary results in early-stage trials for wet Age-Related Macular Degeneration (AMD). The company is actively managing its resources, including workforce reductions, to streamline operations and focus on its most promising drug candidates. Despite the financial losses and ongoing R&D investment, the company believes its existing capital resources are sufficient to meet operating needs through at least mid-2008, with plans for potential future financing.

Regeneron Pharmaceuticals, Inc. (REGN) filed its 2004 annual report on March 10, 2005, detailing its financial condition and operational results for the period ending December 30, 2004. The company's primary focus remains on the development and commercialization of its proprietary antibody-based therapeutics. Investors should note the ongoing research and development activities, which are critical drivers of future growth and potential revenue streams. The company's pipeline and progress in clinical trials, particularly for key drug candidates, represent significant areas of interest for evaluating its long-term prospects.

Regeneron Pharmaceuticals, Inc. (REGN) reported its annual performance for the period ending December 30, 2003, with the filing made on December 13, 2004. The company, a biopharmaceutical firm focused on discovering, developing, and commercializing treatments for serious medical conditions, is heavily invested in its pipeline of product candidates, including VEGF Trap for cancer and eye diseases, IL-1 Trap for rheumatoid arthritis, IL-4/13 Trap for asthma, and AXOKINE® for obesity. As of the reporting period, Regeneron had not yet generated any sales or profits from commercialized products, reflecting its early-stage development nature. The company's strategy centers on leveraging its scientific research and technology platforms to build an integrated biopharmaceutical business. Significant collaboration agreements were highlighted, notably with Aventis for the VEGF Trap and a terminated collaboration with Novartis for the IL-1 Trap, alongside an ongoing collaboration with Procter & Gamble. These partnerships involve substantial upfront payments, milestone opportunities, and shared development expenses, indicating the capital-intensive nature of drug development and Regeneron's reliance on strategic alliances.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious medical conditions. As of the fiscal year ended December 31, 2003, the company had not yet generated any sales or profits from product commercialization, incurring a cumulative loss of $531.5 million since inception. Its pipeline includes product candidates for cancer, eye diseases, rheumatoid arthritis, allergies, asthma, and obesity. Significant collaborations are in place, notably with Aventis for VEGF Trap and previously with Novartis for IL-1 Trap, which was recently terminated by Novartis. The company's financial strategy relies on equity offerings and collaborator funding, with substantial ongoing investment in research and development expected to continue generating losses for the foreseeable future. The company's primary product candidates are VEGF Trap (in Phase I for cancer and eye diseases), IL-1 Trap (in Phase II for rheumatoid arthritis), IL-4/13 Trap (in Phase I for asthma), and AXOKINE (in Phase III for obesity). The company has developed proprietary technology platforms, including Targeted Genomics, Velocigene, and Designer Protein Therapeutics, to aid in drug discovery and development. Despite significant investment and progress, the company faces substantial risks related to clinical trial outcomes, regulatory approvals, competition, and the need for ongoing financing.

Regeneron Pharmaceuticals, Inc.'s 2003 Form 10-K highlights a biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious medical conditions. The company has a diverse pipeline including product candidates for cancer, eye diseases, rheumatoid arthritis, allergies, asthma, and obesity. While Regeneron has made significant strides in its research and development, it has not yet generated any sales or profits from commercialized products, with a cumulative loss since inception. The company is actively pursuing strategic collaborations, notably with Aventis for its VEGF Trap candidate, which provided a significant upfront payment and equity investment. However, a setback was the termination notice from Novartis regarding the IL-1 Trap collaboration, potentially increasing Regeneron's future development costs for this program. Financially, Regeneron reported increased revenues in 2003, largely due to collaboration payments, but also saw a rise in research and development expenses. The company ended 2003 with a strong cash position, bolstered by its equity offerings and collaboration funding, which is expected to sustain operations through at least the end of 2005. Key upcoming developments include the progression of the VEGF Trap into Phase II studies and the initiation of a Phase IIb study for the IL-1 Trap. Investors should closely monitor clinical trial progress, partnership developments, and the company's ability to manage its substantial R&D investments.

Regeneron Pharmaceuticals, Inc., as of its March 31, 2003, 10-K filing, is a biopharmaceutical company in the challenging phase of developing novel drug candidates, having not yet generated any sales or profits. The company's strategy hinges on its proprietary technology platforms, such as Targeted Genomics and Velocigene, to discover and develop treatments for serious medical conditions across obesity, inflammatory diseases, cancer, and more. Its lead product candidate, AXOKINE for obesity, has completed a Phase III trial with statistically significant, though modest, weight loss results. However, the development of antibodies against AXOKINE limited its efficacy, a factor investors should note. The company also has a pipeline of 'Trap' molecules targeting cytokines like IL-1 and VEGF, with IL-1 Trap recently entering a significant collaboration with Novartis. Financially, Regeneron continues to incur substantial operating losses, with R&D expenses constituting the majority of its expenditures, reflecting ongoing investment in its diverse pipeline. While the company had a solid cash position as of year-end 2002, its long-term sustainability relies on successful clinical development, regulatory approvals, and potential future revenue streams. The recent collaboration with Novartis for IL-1 Trap provides a significant funding infusion and development partnership, mitigating some of the financial risks associated with advancing this specific candidate. Investors should closely monitor the progress of AXOKINE through the regulatory process and the advancement of other pipeline candidates, particularly given the inherent risks and long timelines in pharmaceutical development.

Regeneron Pharmaceuticals, Inc. (REGN) filed its 2001 10-K on March 21, 2002. The company, a biopharmaceutical firm focused on discovering, developing, and commercializing therapeutic drugs, reported a significant increase in its net loss for 2001 to $76.2 million from $23.2 million in 2000, primarily due to a substantial rise in research and development expenses. This increase in R&D spending was driven by expanded activities in preclinical and clinical development programs, including the initiation of a Phase III clinical program for AXOKINE® for obesity and a Phase I study for IL1 Trap for rheumatoid arthritis. Despite the growing losses, the company maintained a strong liquidity position, ending 2001 with $438.4 million in cash, cash equivalents, and marketable securities, bolstered by successful public and private offerings of its stock and debt during the year. Regeneron continues to advance a diverse pipeline of product candidates, including AXOKINE for obesity and the IL1 Trap and IL4/IL13 Traps for inflammatory and allergic diseases, with several programs in various stages of clinical development.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics. As of the period ending December 31, 2000, the company had not yet generated any sales or profits from product commercialization. Its strategy centers on leveraging its proprietary technology platforms to build a diverse pipeline of drug candidates targeting serious medical conditions such as obesity, rheumatoid arthritis, cancer, and asthma. Regeneron aims to retain significant ownership and commercialization rights for its key pipeline assets. The company reported a net loss of $23.2 million for the year ended December 31, 2000, a slight increase from the previous year's net loss of $23.1 million. Total revenues for 2000 grew to $59.3 million, up from $34.5 million in 1999, driven by increased contract research and development, and contract manufacturing revenues, particularly from collaborations with Procter & Gamble and Merck. Research and development expenses also rose to $56.3 million in 2000, reflecting ongoing investment in its pipeline. Regeneron's liquidity position remained strong, with $154.4 million in cash, cash equivalents, and marketable securities as of December 31, 2000, and management anticipated sufficient funding through the third quarter of 2002.

Regeneron Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 30, 1999, on March 6, 2000. As a biopharmaceutical company, Regeneron's financial health and future prospects are intrinsically tied to its research and development pipeline, regulatory approvals, and commercialization efforts. Investors would have been focused on the company's progress in developing its drug candidates and potential market opportunities. Given the filing date in early 2000, the company was operating in a dynamic period for the biotechnology sector. Key areas of interest for investors would include the status of its lead product candidates, any strategic partnerships or collaborations, the competitive landscape, and the company's financial position to fund ongoing research and clinical trials. The filing would provide a comprehensive overview of the company's operations, financial statements, and risk factors.

Regeneron Pharmaceuticals, Inc.'s 1998 10-K filing provides a snapshot of the company's operational and financial standing as of December 30, 1998. As a biotechnology company, Regeneron was heavily focused on research and development, with significant investment in its pipeline of therapeutic candidates. The filing likely details its lead product candidates, potential market opportunities, and the considerable risks associated with drug development, including regulatory hurdles and clinical trial outcomes. Investors in Regeneron at this time would be assessing the company's progress in its key therapeutic areas, its financial resources to fund ongoing R&D, and its strategic partnerships or collaborations. The 10-K would be crucial for understanding the company's long-term growth potential, the competitive landscape, and the inherent uncertainties in bringing novel pharmaceuticals to market. Particular attention would be paid to any advancements in their proprietary gene-transfer technology and its application to various diseases.

Regeneron Pharmaceuticals, Inc.'s 1997 10-K filing, filed on March 26, 1998, details the company's status as a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutic drugs. At this stage, Regeneron was heavily invested in research and development, with a focus on its antibody-based therapeutics. The filing would have provided insights into its pipeline, partnerships, and the financial resources required to advance its drug candidates through clinical trials and toward potential market approval.

Regeneron Pharmaceuticals, Inc. (REGN) filed this 10-K/A amendment on May 30, 1997, for the period ending December 30, 1996. As a biotechnology company, its focus would be on research and development of novel therapeutics. Investors would be keen to understand the company's progress in its drug pipeline, clinical trials, and potential for future commercialization. The filing likely details financial performance, risk factors, and management's outlook, all crucial for assessing the company's growth prospects and investment potential in the rapidly evolving biotech sector.

Regeneron Pharmaceuticals, Inc. (REGN) filed its 1996 10-K on March 25, 1997, detailing its financial performance and operational activities for the fiscal year ending December 30, 1996. As a biotechnology company, Regeneron's focus remained on research and development of therapeutic proteins. The filing provides a snapshot of the company's early-stage development and its strategic direction as it navigated the complex and capital-intensive pharmaceutical industry. Investors should note that this filing represents a period when the company was likely heavily investing in its pipeline with limited product revenues. The report would contain detailed information on its lead drug candidates, ongoing clinical trials, research collaborations, and its financial position, including cash reserves and funding strategies. Understanding these aspects is crucial for assessing the long-term growth potential and associated risks of Regeneron at this stage of its corporate evolution.